BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 9796043)

  • 21. From the Centers for Disease Control and Prevention. Measles--United States, 1996, and the interruption of indigenous transmission.
    JAMA; 1997 May; 277(17):1345-6. PubMed ID: 9134928
    [No Abstract]   [Full Text] [Related]  

  • 22. Measles, mumps, and rubella vaccines.
    Wharton M; Cochi SL; Williams WW
    Infect Dis Clin North Am; 1990 Mar; 4(1):47-73. PubMed ID: 2407778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The significance of epidemiological studies for progress of measles elimination].
    Mrozek-Budzyn D
    Przegl Epidemiol; 2010; 64(3):361-6. PubMed ID: 20976947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Issues related to rubella, measles and epidemic parotiditis in the Russian Federation].
    Zverev VV; Iuminova NV
    Vopr Virusol; 2004; 49(3):8-11. PubMed ID: 15188648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The end of measles and congenital rubella: an achievable dream?
    Adamo G; Sturabotti G; D'Andrea E; Baccolini V; Romano F; Iannazzo S; Marzuillo C; Villari P
    Ann Ig; 2017; 29(1):1-26. PubMed ID: 28067934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children.
    Higginson D; Theodoratou E; Nair H; Huda T; Zgaga L; Jadhav SS; Omer SB; Rudan I; Campbell H
    BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S31. PubMed ID: 21501450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of Measles in Korea: Quarantine and Elimination.
    Kang JH
    Infect Chemother; 2020 Mar; 52(1):113-122. PubMed ID: 32239813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A model to estimate the potential economic benefits of measles eradication for the United States.
    Miller MA; Redd S; Hadler S; Hinman A
    Vaccine; 1998 Dec; 16(20):1917-22. PubMed ID: 9796043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measles control in developing and developed countries: the case for a two-dose policy.
    Tulchinsky TH; Ginsberg GM; Abed Y; Angeles MT; Akukwe C; Bonn J
    Bull World Health Organ; 1993; 71(1):93-103. PubMed ID: 8440043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.
    Bart KJ; Orenstein WA; Hinman AR
    Dev Biol Stand; 1986; 65():45-52. PubMed ID: 3104117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effectiveness, population-level effects, and heath economics of measles and rubella vaccination].
    Wichmann O; Ultsch B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1260-9. PubMed ID: 23990088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enabling implementation of the Global Vaccine Action Plan: developing investment cases to achieve targets for measles and rubella prevention.
    Thompson KM; Strebel PM; Dabbagh A; Cherian T; Cochi SL
    Vaccine; 2013 Apr; 31 Suppl 2():B149-56. PubMed ID: 23598476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consensus conference on measles.
    Can Commun Dis Rep; 1993 May; 19(10):72-9. PubMed ID: 8348101
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.